Figure 5
Sensitivity of CD24+/CD44+ and CD24-/CD44+ cells to cisplatin and gemcitabine anticancer drugs. Flow cytometry sorted cells were exposed to cisplatin (A), and gemcitabine (B) at increasing concentrations for 72 hr, followed by cell viability measurement by Cell Titter-Glo® Cell Viability Assay. Differences in drug resistance between CD24+/CD44+ and CD24-/CD44+ cells were calculated. All experiments were performed in triplicate and data are shown as mean ± SD. Data in inset show statistical significance at p < 0.01 for both treatments.